With seven sites across Europe and the US, KD Pharma aims to add on to the growing omega-3 active pharmaceutical ingredient (API) market. The company produces omega-3 products for the use in finished products, such as soft gel capsules and bottled liquid forms of pharmaceutical products.
With the acquisition of the UK manufacturing site, KD Pharma will be able to meet the market demand for supplying the omega-3 APIs for product approvals, label expansions, and clinical research of drug candidates.
Oscar Groet, CEO of KD Pharma, said in a statement that this site acquisition will expand the company’s technology and manufacturing base for producing API’s that have the highest concentrations of EPA and DHA omega-3s.
The Seal Sands site, which was previously used for the manufacturing of omega-3 products, will be brought online for intermediate production later this year.